JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Review
Tumor markers: when, whom?
Abstract
Cancer is a leading health problem with its prevalence, clinical course and deaths all over the world. It is known that cancer is the second leading cause of death in Turkey after cardiovascular diseases. Therefore, intensive research is carried out on the early diagnosis and treatment of cancer. The most important of these are tumor markers that are still used in clinical practice. Based on this definition, it is theoretically possible to obtain information about the presence of the tumor and the character of the tumor by investigating tumor markers in body fluids. A tumor marker is a molecule that is present in the structure of the tumor cell, secreted by the tumor cell or produced in response to the tumor and can be measured or demonstrated in body fluids. However, its use is limited due to its low sensitivity and specificity to cancer type in the early period. Therefore, it is important to select the appropriate test at the appropriate time for the appropriate patient. In this review, general principles regarding the use of tumor markers were tried to be explained.

Keywords : Tumor markers, cancer, early diagnosis

Download Article


1. Sadighbayan D, Sadighbayan K, Tohid-Kia MR, Khosroushahi AY,Hasanzadeh M. Development of electrochemical biosensors for tumormarker determination towards cancer diagnosis: Recent progress.TrACTrends in Analytical Chemistry. 2019;118:73-88.
2. Necula L, Matei L, Dragu D, et al. Recent advances in gastric cancerearly diagnosis.World J Gastroenterol. 2019:25(17):2029.
3. Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36cancers in 185 countries.CA Cancer J Clin.2021:71:209-249. https://doi.org/10.3322/caac. 2166
4. Erridge S, Lyratzopoulos G, Renzi C, Millar A, Lee R. RapidDiagnostic Centres and early cancer diagnosis.British J GeneralPractice.2021;71(712):487-488.
5. Chaturvedi VK, Singh A, Singh VK, Singh MP. Cancer nanotechnology:a new revolution for cancer diagnosis and therapy.Curr DrugMetab.2019;20(6):416-429.
6. https://hsgm.saglik.gov.tr/tr/kanser-istatistikleri/yillar/2017-turkiye-kanser-i-statistikleri.html
7. https://www.drozdogan.com/turkiye-kanser-istatistikleri-2020/
8. Huang Y,Yang S,Zhang J,et al.MicroRNAs as Promising Biomarkersfor Diagnosing Human Cancer.Cancer Investigation. 2010;28:6:670-671.
9. Duffy MJ. Clinical uses of tumor markers: a critical review. Crit RevClin Lab Sci. 2001;38:225-262. Doi.10.1080/20014091084218
10. https://www.turkbiyokimyadernegi.org.tr/upload/48/Dosyalar/tmp/201837165221.pdf
11. Duffy MJ: Tumor markers in clinical practice: a review focusingon common solid cancers. Med Princ Pract. 2013;22:4-11. Doi.10.1159/000338393
12. Nagpal M, Singh S, Singh P, Chauhan P, Zaidi MA. Tumor markers:a diagnostic tool. Natl J Maxillofac Surg. 2016;7(1):17-20. doi:10.4103/0975-5950.196135
13. Sharma S. Tumor markers in clinical practice: General principles andguidelines. Indian J Med Paediatr Oncol. 2009;30(01):1-8.
14. Nah EH, Cho S, Park H, Kim S, Kwon E, Cho HI. Establishment andvalidation of reference intervals for tumor markers (AFP, CEA, CA19-9,CA15-3, CA125, PSA, HE4, Cyfra 21-1, and ProGRP) in primary carecenters in Korea: a cross-sectional retrospective study.Health ScienceReports. 2023;6(2):e1107.
15. Grenache DG. Progress in understanding the use of humanchorionic gonadotropin as a tumor marker.Clin Chem Lab Med(CCLM).2020;58(3):323-325.
16. Eriksson B, Öberg K, Stridsberg M. Tumor markers in neuroendocrinetumors. Digestion 2000;62(suppl 1):33-38. doi: 10.1159/000051853
17. Çelik S, Aslan G. Testis tümör belirteçleri ve tanı modelitelerindekigüncel gelişmeler.Kanser Gündemi Dergisi. 2020;8(2):13-18.
18. Gündoğdu Ü. Gastrointestinal ve meme malign neoplasmlıpreoperatif hastalarda, CEA, CA 19-9, CA 15-3, CA 125 ve AFPtümör biyobelirteçlerinin prognostik değeri.Euroasia J Mathematics,Engineering Nat Med Sci. 2020;7(11):88-95.
19. Alanbay İ, Çoksüer H, Ercan CM. Jinekolojik onkolojide tümörbelirteçleri: Literatür Derleme.Kocatepe Tıp Dergisi.2011;12(3):57-163.
20. Sisinni L, Landriscina M. The role of human chorionic gonadotropinas tumor marker: biochemical and clinical aspects. In: Scatena, R. (eds)Advances in cancer biomarkers. Advances in Experimental Medicineand Biology. 2015:867. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7215-0_11
21. Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as abiomarker for breast cancer.Clin Chim Acta. 2010;411(23-24):1869-1874. doi:10.1016/j.cca.2010.08.039
22. Üçüncü MZ. Kolorektal kanserlerin tanı ve prognostik takibinde eskive yeni serum biyobelirteçleri: sistematik inceleme ve meta-analiz.İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi. 2019;9:902-919.Doi: 10.38079/igusabder.592956
23. Hall C, Clarke L, Pal A, et al. A review of the role of carcinoembryonicantigen in clinical practice.Ann Coloproctol. 2019;35(6):294-305.doi:10.3393/ac.2019.11.13
24. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer:Is it clinically useful?Clin Chem 2001;47(4):624-630,https://doi.org/10.1093/clinchem/47.4.624
25. Çetinkaya M, Erdoğan Ö, Deliktaş H, Şahin H. Prostat spesifik antijen(PSA). Muğla Sıtkı Koçman Üniv Tıp Derg. 2015;2(2),67-77. Retrievedfrom https://dergipark.org.tr/tr/pub/muskutd/issue/ 34649/382831
26. Özman O, Talat Z, Erözenci A. Prostat spesifik antijen’in tarihi.”MersinÜniversitesi Tıp Fakültesi Lokman Hekim Tıp Tarihi ve Folklorik TıpDergisi. 2019;9(2):184-188.
27. Yencilek F, Koca O, Kuru M. Prostat kanserinde tanı. Nucl Med Semin.2018;4(3):163-173.
28. Burak Z, Tamer F, Gümüş M. Tiroid kanseri izleminde tiroglobulinölçümünün yeri ve önemi. Nucl Med Semin 2021;7:47-54.
29. Passek K, Zulauf N, Bendels MH, Quarcoo D, Oremek GM. The tumormarker thyroglobulin.Zentralblatt für Arbeitsmedizin, Arbeitsschutzund Ergonomie. 2020;70:40-43.
Article available in :
Volume 1, Issue 1, 2023
Page : 9-11
https://doi.org/10.51271/JCHOR-0003
Article Information
Received : 20 Şub 2023
Accepted : 22 Şub 2023
Published : 26 Şub 2023
Corresponding Author :

Artuner Varlıbaş: Department of Internal Medicine, Faculty of Medicine, Kırıkkale University, Kırıkkale, Turkey

[email protected]
Citation : Varlıbaş A, Çifci A. Tumor markers: when, whom?. J Curr Hematol Oncol Res. 2023; 1(1): 9-11

Read: 232
Cited: 0
Download : 279
_Footer